Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardiAQ gets backing from former CoreValve investors

This article was originally published in Clinica

Executive Summary

CardiAQ Valve Technologies, a firm developing a novel technology for transcatheter mitral valve implantation, has raised $6.5m in series A financing. Winchester, Massachusetts-based CardiAQ Valve will use the proceeds to validate its technology – claimed to be the first of its kind to have self-conforming and self-anchoring features – and take it through to first-in-man studies. The financing was led by a syndicate of private investors who had previously backed CoreValve, a company which specialises in percutaneous aortic valve replacement. CoreValve was bought by Medtronic in February 2009. Among the investors in CardiAQ is former president and chief operating officer of CoreValve, Rob Michiels. Mr Michiels was elected to CardiAQ’s board of directors in September last year (www.clinica.co.uk, September 22 2009). Broadview Ventures, which made an earlier investment in CardiAQ, also contributed to the series A round. According to CardiAQ, the mitral valve market is estimated to grow to $1.2bn by 2014.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

MT045211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel